Novo Nordisk A/S (NYSE:NVO) vs. VBI Vaccines (NYSE:VBIV) Head-To-Head Comparison

VBI Vaccines (NASDAQ:VBIV) and Novo Nordisk A/S (NYSE:NVO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Valuation & Earnings

This table compares VBI Vaccines and Novo Nordisk A/S’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $3.36 million 42.82 -$63.60 million ($0.97) -0.83
Novo Nordisk A/S $17.72 billion 7.62 $5.91 billion $2.52 22.65

Novo Nordisk A/S has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

VBI Vaccines has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares VBI Vaccines and Novo Nordisk A/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -1,458.97% -70.54% -49.52%
Novo Nordisk A/S 32.44% 75.48% 33.41%

Insider and Institutional Ownership

40.9% of VBI Vaccines shares are owned by institutional investors. Comparatively, 7.3% of Novo Nordisk A/S shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for VBI Vaccines and Novo Nordisk A/S, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 3 0 3.00
Novo Nordisk A/S 1 6 4 0 2.27

VBI Vaccines currently has a consensus target price of $4.33, indicating a potential upside of 436.90%. Novo Nordisk A/S has a consensus target price of $181.58, indicating a potential upside of 218.16%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Novo Nordisk A/S.

Summary

Novo Nordisk A/S beats VBI Vaccines on 8 of the 14 factors compared between the two stocks.

VBI Vaccines Company Profile

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit